Results 41 to 50 of about 23,348 (143)

Current clinical evidence on pioglitazone pharmacogenomics

Frontiers in Pharmacology, 2013
Pioglitazone is the most widely used thiazolidinedione and acts as an insulin-sensitizer through activation of the Peroxisome Proliferator-Activated Receptor-γ (PPARγ).
Marina eKawaguchi-Suzuki, Reginald F. Frye   +1 more
doaj   +1 more source

Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes. [PDF]

PLoS ONE, 2015
BACKGROUND:Despite its insulin sensitizing effects, pioglitazone may induce weight gain leading to an increased risk of development of insulin resistance.
Yoshinori Watanabe, Keiko Nakayama, Nobuhiko Taniuchi, Yasushi Horai, Chiaki Kuriyama, Kiichiro Ueta, Kenji Arakawa, Takaaki Senbonmatsu, Masaharu Shiotani   +8 more
doaj   +1 more source

Mitochondrial nutrients improve immune dysfunction in the type 2 diabetic Goto-Kakizaki rats. [PDF]

, 2008
The development of type 2 diabetes is accompanied by decreased immune function and the mechanisms are unclear. We hypothesize that oxidative damage and mitochondrial dysfunction may play an important role in the immune dysfunction in diabetes.
Hao, Jiejie, Liu, Jiankang, Liu, Zhongbo, Long, Jiangang, Luo, Cheng, Ren, Jinmin, Sharman, Edward, Shen, Weili, Tian, Chuan   +8 more
core   +1 more source

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

The anti-atherogenic effects of thiazolidinediones [PDF]

, 2007
The thiazolidinediones (TZDs) rosiglitazone (ROS) and pioglitazone (PIO) are insulin-sensitising agents widely used to treat patients with type 2 diabetes mellitus (T2DM). Thiazolidinediones significantly improve glycaemic control in diabetics by reduced
Honisett, Suzy, Komesaroff, Paul A, Stojanovska, Lily   +2 more
core  

Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation [PDF]

, 2019
Neurodegenerative diseases are characterized by a progressive loss of neurons that leads to a broad range of disabilities, including severe cognitive decline and motor impairment, for which there are no effective therapies.
Codocedo, Juan F., Landreth, Gary E., Moutinho, Miguel, Puntambekar, Shweta S.   +3 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study

Indian Journal of Endocrinology and Metabolism, 2015
Aim: To determine whether pioglitazone is associated with an increased risk of bladder cancer among Indian type 2 diabetic patients. Methods: A retrospective data analysis of 2222 type 2 diabetic patients was conducted.
Sunil Gupta, Kavita Gupta, R Ravi, Vinita Mehta, Samar Banerjee, Shashank Joshi, Banshi Saboo   +6 more
doaj   +1 more source

Pioglitazone Reverses Markers of Islet Beta-Cell De-Differentiation in db/db Mice While Modulating Expression of Genes Controlling Inflammation and Browning in White Adipose Tissue from Insulin-Resistant Mice and Humans

Biomedicines, 2021
Obesity, insulin resistance, and type 2 diabetes contribute to increased morbidity and mortality in humans. The db/db mouse is an important mouse model that displays many key features of the human disease.
J. Jason Collier, Heidi M. Batdorf, Kaelan L. Merrifield, Thomas M. Martin, Ursula White, Eric Ravussin, David H. Burk, Chris R. Cooley, Michael D. Karlstad, Susan J. Burke   +9 more
doaj   +1 more source

The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: A bench to bedside review [PDF]

, 2014
INTRODUCTION: The treatment of type 2 diabetes mellitus (T2DM) continues to pose challenges for clinicians and patients. The dramatic rise in T2DM prevalence, which has paralleled the rise in obesity, has strained the healthcare system and prompted the ...
McGill, Janet B
core   +2 more sources